Relief Therapeutics Holding AG (RLFTF)

[rollup]

From the YF - Report from Jan 21

This was culled from a research report of the aviptadil clinical trial at Methodist Hospital, Houston:

"KEY POINTS
Question: Does intravenous aviptadil (Vasoactive Intestinal Peptide) improve survival and recovery from respiratory failure in patients with Critical COVID-19 and major comorbidity.

Findings: In this administratively-controlled clinical trial, intravenous aviptadil, administered as 3 successive 12 hour infusions of 50/100/150 pmol/kg/hr resulted in a 9-fold advantage in both survival and recovery from respiratory failure compared to standard of care with all approved therapy for COVID-19 among patients treated in the same ICU by the same clinical care team. Notably, 4 of 5 aviptadil-treated patients on Extracorporeal Membrane Oxygenation were successfully decannulated and survived, compared to 3 of 13 control patients. Although 20% of patients exhibited hypotension and/or diarrhea, no drug-related serious adverse events were seen.

Meaning: Intravenous aviptadil demonstrated a dramatic level of efficacy that is consistent with FDA guidance for administratively-controlled clinical trials and may be warranted for use in highly-comorbid patients with Critical COVID-19 and respiratory failure."